Gradual dose escalation as recommended in UK prescribing information helps minimise these effects
"These medications are supposed to help, not cause more harm," Dr
In the SURPASS-4 trial, patients receiving tirzepatide experienced an average weight loss of 7.1 kg (15.7 lbs) after 52 weeks, compared to 2.5 kg (5.5 lbs) in the insulin glargine group[6]
The FLOW trial The FLOW trial was a double-blind, placebo-controlled clinical trial designed to test whether semaglutide (the active ingredient in Ozempic) could protect kidney function in people with type 2 diabetes and chronic kidney disease
Detection in Doping Analysis Mongongu et al., Drug Testing and Analysis (2021) Mongongu and colleagues at the French Anti-Doping Laboratory developed and validated a sensitive analytical method for detecting Long-R3-IGF-I, Des(13)-IGF-I, and R3-IGF-I in human serum using immunopurification followed by nano-liquid chromatography coupled with high-resolution mass spectrometry
Repeat reactions may require dose adjustment or ingredient exclusion
